Scarica l'app Stockscreener
0.4894
2.12%
-0.0106
Pre-mercato:
.49
0.0006
+0.12%
Precedente Chiudi:
$0.50
Aprire:
$0.47
Volume 24 ore:
400.44K
Relative Volume:
0.04
Capitalizzazione di mercato:
$21.64M
Reddito:
$106.79M
Utile/perdita netta:
$-8.73M
Rapporto P/E:
-2.447
EPS:
-0.2
Flusso di cassa netto:
$10.81M
1 W Prestazione:
-4.80%
1M Prestazione:
+13.66%
6M Prestazione:
-63.75%
1 anno Prestazione:
-82.58%
Intervallo 1D:
$0.4664
$0.499
Intervallo di 1 settimana:
$0.4664
$0.539
Portata 52W:
$0.2813
$3.27
Harvard Bioscience Inc Stock (HBIO) Company Profile
Nome
Harvard Bioscience Inc
Settore
Industria
Telefono
(508) 893-8999
Indirizzo
84 OCTOBER HILL RD, HOLLISTON, MA
Confronta HBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.4894 | 22.11M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
477.08 | 172.91B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.00 | 56.17B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
86.79 | 42.77B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
284.72 | 42.21B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.20 | 17.71B | 2.90B | 467.20M | 306.90M | 6.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | Iniziato | Northland Capital | Outperform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | Downgrade | Janney | Buy → Neutral |
| 2018-01-24 | Reiterato | Janney | Buy |
| 2018-01-23 | Reiterato | The Benchmark Company | Buy |
| 2016-11-17 | Iniziato | Singular Research | Buy |
| 2015-07-28 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Harvard Bioscience Inc Borsa (HBIO) Ultime notizie
Is Harvard Bioscience Inc. a good stock for dollar cost averagingMarket Weekly Review & Short-Term Swing Trade Alerts - sundaytimes.kr
How Harvard Bioscience Inc. stock performs during market volatility2025 Short Interest & Fast Gain Swing Trade Alerts - sundaytimes.kr
Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target - simplywall.st
Harvard Bioscience enters retention agreement with interim CFO Mark Frost By Investing.com - Investing.com Nigeria
Harvard Bioscience Offers CFO $100K Retention Bonus - TipRanks
Harvard Bioscience enters retention agreement with interim CFO Mark Frost - Investing.com India
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Harvard Bioscience 2025 Q2 Earnings Narrows Losses with 22% Drop in Net Loss - AInvest
Harvard Bioscience Amends Credit Agreement with Lenders Amid Concerns Over Future Operations - AInvest
Is Now a Good Time to Reenter Harvard Bioscience Inc.Target Return Focused Trade Insights Shared - sundaytimes.kr
Harvard Bioscience: Q2 Earnings Snapshot - Norwalk Hour
Harvard Bioscience Inc (HBIO) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Harvard Bioscience Reports Q2 2025 Financial Results - TipRanks
Harvard Bioscience Q2 2025: Unpacking Contradictions in NIH Funding, Refinance Terms, and China Market Outlook - AInvest
Harvard Bioscience Amends Credit Agreement with Lenders - TipRanks
Harvard Bioscience Delivers Steady Results And Eyes Growth Ahead - Finimize
Harvard Bioscience Delivers Steady Results And Improved Cash Flow - Finimize
Harvard Bioscience outlines $19M–$21M Q3 revenue target as debt refinancing advances and product adoption accelerates - MSN
Harvard Bioscience Q2 2025 Earnings Call Transcript - MarketBeat
Harvard Bioscience Exceeds Revenue Estimate in Q2 2025, Reports $20.5 Million in Revenue and a Loss Per Share of $0.05 - AInvest
Harvard Bioscience: Navigating Debt and Innovation in the Biotech Tools Sector - AInvest
Harvard Bioscience sets Q3 revenue target at $19M-$21M, CEO outlines priorities for 2025. - AInvest
Harvard Bioscience earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Earnings call transcript: Harvard Bioscience Q2 2025 results show mixed signals - Investing.com Nigeria
Transcript : Harvard Bioscience, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Harvard Bioscience Q2 2025 slides: improved profitability despite revenue challenges By Investing.com - Investing.com South Africa
Harvard Bioscience Q2 2025 slides: improved profitability despite revenue challenges - Investing.com Nigeria
Harvard Bioscience's Q2 2025 Performance: A Strategic Turnaround Amid Debt Refinancing Challenges - AInvest
Harvard Bioscience Reports Q2 Earnings Beat, Initiates Q3 Outlook - AInvest
Harvard Bioscience Tops Q2 Revenue Views - The Motley Fool
Harvard Bioscience Tops Q2 Revenue Views - The Globe and Mail
Harvard Bioscience Q2 revenue meet estimates - MarketScreener
Harvard Bioscience : Q2 2025 Harvard Bioscience, Inc. Earnings Conference Call - MarketScreener
Harvard Bioscience Q2 2025 Financial Results - TradingView
Harvard Bioscience Announces Second Quarter 2025 Financial Results - GlobeNewswire
Harvard Bioscience Q2 Earnings: Revenue Beats Guidance as New CEO Charts Turnaround Path - Stock Titan
Will Harvard Bioscience Inc. benefit from macro trendsFree High Conviction Intraday Stock Signals - Newser
Harvard Bioscience Inc. stock daily chart insights2-Day Signal Watch with Forecast Outcome - Newser
Harvard Bioscience Inc. stock outlook for YEARStock Entry Points Based on Technicals - Newser
Why Harvard Bioscience Inc. stock attracts strong analyst attentionFree Real Time Alerts Based on AI Prediction - Newser
Relative strength of Harvard Bioscience Inc. in sector analysisFree Alert Feed for Momentum Based Picks - Newser
What earnings revisions data tells us about Harvard Bioscience Inc.Free Weekly Potential Breakout Stock List - Newser
Is Harvard Bioscience Inc. stock poised for growthReal Chart Based Opportunity Identification - Newser
Real time scanner hits for Harvard Bioscience Inc. explainedFree Proven Entry Plan With Low Risk Trade - Newser
Harvard Bioscience HBIO 2025Q2 Earnings Preview Upside Anticipated on Innovative Gene Therapy Developments - AInvest
Harvard Bioscience Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Earnings To Watch: Harvard Bioscience Inc (HBIO) Reports Q2 2025 Result - Yahoo Finance
Chart overlay techniques for tracking Harvard Bioscience Inc.AI Intraday Market Movement Prediction Tool - Newser
Harvard Bioscience announces CEO succession plan - MSN
Harvard Bioscience Sets Q2 2025 Earnings Release and Conference Call - AInvest
Harvard Bioscience, Inc. to Release Q2 2025 Financial Results and Host Conference Call on August 11, 2025 - Quiver Quantitative
Harvard Bioscience Inc Azioni (HBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.96%
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):